Could a vitamin B12 shot help kids with MMA? new trial underway

NCT ID NCT07163364

Not yet recruiting Disease control Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase III trial tests a vitamin B12 injection (hydroxocobalamin chloride) in 20 children aged 6 months to 18 years with a specific type of methylmalonic acidemia (cobalamin C deficiency). The goal is to see if the injection can normalize levels of certain acids in the blood or urine. Participants will receive the injection 1 to 5 times per week for maintenance therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hydroxocobalamin chloride injection (a form of vitamin B12)
What this could lead to: If successful, this could provide a more effective maintenance therapy for children with a specific type of methylmalonic acidemia, helping to normalize key disease markers.
What could go wrong: This is a small, single-arm, open-label trial with only 20 participants, so results may not be generalizable. There is no placebo group, and the primary outcome is a lab marker, not long-term clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates